SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Nuvectis Reports 40% Response Rate in Phase 1b Glioma Study

Nuvectis reported a 40% response rate for NXP200 in a Phase 1b high-grade glioma study.

NVCT

Related stories